Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 3 of 151

  1. 20170104

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  2. 20170512

    The First People's Hospital of Lianyungang

    Triple-Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  3. 20180257

    Amgen

    Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,

    phase 2 small molecule active

    1 trial

  4. 2020-004696-41

    The George Institute

    Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  5. 2020-S112

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

  6. 2020/3093 NIRADO

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  7. 202000570

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  8. 20200491

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. 2021-SR-545

    The First People's Hospital of Lianyungang

    Lymphoma, Large B-Cell, Diffuse

    phase 2 small molecule active

    1 trial

  10. 2021/3330 HOLMBRAVE

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  11. 20210023

    Amgen

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  12. 20210210

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  13. 2022/3418 INDIGO

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  14. 20220127

    Amgen

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. 2023-1-69-001

    Ningbo Cancer Hospital

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  16. 2023-508254-26-00

    Disc Medicine

    Primary aldosteronism

    phase 2 other active

    1 trial

  17. 2023-SR-002

    The First People's Hospital of Lianyungang

    NK-T-Cell Lymphoma, Extranodal

    phase 2 small molecule active

    1 trial

  18. 2023/3610 NEOSARC

    The George Institute

    Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma

    phase 2 small molecule active

    1 trial

  19. 2023/3668

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  20. 20230302

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  21. 2024-512318-16-00

    Disc Medicine

    Patients with colorectal peritoneal metastases with a PCI-score of 1-20

    phase 2 small molecule active

    1 trial

  22. 2024-HS-022

    The First People's Hospital of Lianyungang

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  23. 2024/3967

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  24. 20240092

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  25. 2025-206

    The First People's Hospital of Lianyungang

    Radiation - Induced Proctitis

    phase 2 small molecule active

    1 trial

  26. 2025-521139-35-01

    Disc Medicine

    Primary membranous nephropathy

    phase 2 small molecule active

    1 trial

  27. 2025-521877-14-00

    The George Institute

    Traumatic spinal cord injury

    phase 2 other active

    1 trial

  28. 2025-SR-813

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  29. 2026-525211-14-00

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  30. 2026（225）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer of Biliary Duct

    phase 2 small molecule active

    1 trial

  31. 20289

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  32. 20290

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  33. 20433A

    H. Lundbeck A/S

    Cushing's Disease

    phase 2 other active

    1 trial

  34. 206882

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  35. 208887

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  36. 209628

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 other active

    1 trial

  37. 212580

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  38. 213357

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

  39. 213403

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  40. 213824

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  41. 217043

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  42. 21773

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  43. 218307

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  44. 21839

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  45. 219231

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  46. 219590

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  47. 219867

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  48. 22040

    Bayer AG

    Chronic kidney disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.